Atrial Fibrillation

Atrial fibrillation in the intensive care unit requires a structured management approach centered on ventricular rate control, restoration of sinus rhythm, and prevention of thromboembolic complications. Hemodynamic stability dictates the urgency of intervention; patients presenting with shock, pulmonary edema, or myocardial ischemia necessitate immediate electrical cardioversion, while stable patients are managed pharmacologically with beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin. Because atrial fibrillation often stems from multifactorial triggers—including post-operative adrenergic surges, inflammation, and structural heart disease—clinicians must carefully weigh the risks of anticoagulation against the potential for life-threatening hemorrhage. Furthermore, patients with Wolf-Parkinson-White syndrome require specific caution, as standard rate-control agents can paradoxically accelerate conduction. Successful long-term rhythm maintenance remains challenging, particularly in patients with dilated left atria or prolonged arrhythmia duration, necessitating continued vigilance and potential long-term anticoagulation to mitigate post-cardioversion embolic risks.